Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXEDRINE vs BROMOCRIPTINE MESYLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
FDA-approved: Treatment of hyperprolactinemia (including amenorrhea/galactorrhea, hypogonadism, infertility) associated with prolactin-secreting adenomas,FDA-approved: Adjunctive treatment of Parkinson disease (idiopathic or postencephalitic),FDA-approved: Treatment of acromegaly (as an adjunct to surgery or radiotherapy),Off-label: Type 2 diabetes mellitus (improves glycemic control),Off-label: Neuroleptic malignant syndrome,Off-label: Prevention of postpartum lactation (use not recommended due to serious adverse events)
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Primarily metabolized by CYP2D6 to 4-hydroxydextroamphetamine, which is further metabolized to various metabolites. Also undergoes deamination and oxidation.
Extensively metabolized primarily by cytochrome P450 3A4 (CYP3A4) to multiple metabolites, including the major active metabolite 2-bromo-α-ergocriptine. Also undergoes non-CYP-mediated hydrolysis and conjugation. First-pass metabolism is significant, resulting in ~6% oral bioavailability.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Approximately 16-20% bound; primarily to albumin
90-96% bound to serum albumin, with some binding to alpha-1-acid glycoprotein.
3.5-4.5 L/kg; indicates extensive tissue distribution, particularly CNS
Approximately 2-3 L/kg, indicating extensive tissue distribution and penetration into breast milk and central nervous system.
Oral: 75-100% (immediate-release), 70-90% (extended-release); rectal and parenteral routes are not clinically utilized
Oral: 28-30% due to extensive first-pass metabolism; sublingual: 40-50% due to partial avoidance of hepatic first-pass; rectal: approximately 20%.
GFR 15–30 m L/min: use with caution, consider dose reduction by 50%. GFR <15 m L/min: not recommended.
No specific dose adjustment recommended; monitor for accumulation in severe renal impairment (e GFR <30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use.
Age 3–5 years: 2.5 mg orally once daily, increase by 2.5 mg weekly as needed (max 40 mg/day). Age ≥6 years: 5 mg orally once or twice daily, increase by 5 mg weekly (max 40 mg/day).
Prolactinomas: 1.25-2.5 mg/m²/day orally in 2-3 divided doses; titrate based on response. Weight-based: 0.01-0.02 mg/kg/day, increase slowly.
Start at lowest dose (2.5–5 mg orally once daily), titrate slowly; monitor for cardiovascular effects, agitation, and weight loss.
Initiate at low end of dosing range (1.25 mg once or twice daily) due to increased sensitivity and risk of hypotension; titrate slowly.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including DEXEDRINE, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
None
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, manic episodes, and aggression,Seizures in patients with prior seizure history,Long-term suppression of growth in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when co-administered with serotonergic drugs
May cause hypotension (especially postural), syncope, and severe adverse reactions such as myocardial infarction, stroke, seizures, and psychosis. Can cause pleural and retroperitoneal fibrosis, pericarditis, and valvulopathy (especially with high doses for Parkinson disease). Has been associated with pathological gambling, hypersexuality, and impulse control disorders. May cause somnolence and sudden sleep onset. Monitor for cardiac valvulopathy and pulmonary fibrosis. Use with caution in patients with cardiovascular disease, peptic ulcer disease, or a history of mental illness.
Known hypersensitivity to amphetamine products or other components of DEXEDRINE,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis),Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Absolute: Hypersensitivity to bromocriptine or ergot alkaloids; uncontrolled hypertension; pregnancy (toxemia of pregnancy); preeclampsia/eclampsia; coronary artery disease or other significant cardiovascular disease; severe renal or hepatic impairment. Relative: History of peptic ulcer disease, psychiatric disorders, Raynaud phenomenon, or hepatic impairment.
Avoid high-fat meals with immediate-release formulations as they may delay absorption; for extended-release, high-fat meals can increase peak concentration. Acidic foods (e.g., citrus fruits, fruit juices, carbonated drinks) can reduce absorption. Avoid excessive caffeine (coffee, tea, energy drinks) as it may exacerbate central nervous system stimulation and cardiovascular effects. Maintain adequate hydration. Grapefruit and other CYP2D6 inhibitors may increase effects.
Take with food to reduce gastrointestinal irritation; avoid high-protein meals if using for hyperprolactinemia as protein may decrease absorption.
First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (hyperactivity, irritability, feeding difficulties). Dextroamphetamine is a sympathomimetic amine with potential for vasoconstriction reducing uteroplacental perfusion.
First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage due to uterine atony; may suppress pituitary prolactin, potentially impairing placental lactogen production. Overall, use only if clearly needed.
Dextroamphetamine is excreted into breast milk; M/P ratio not established but concentration about 2-7 times maternal plasma. potential for infant stimulation, insomnia, and growth impairment. American Academy of Pediatrics recommends use during breastfeeding only if benefits outweigh risks; monitor infant for agitation and poor weight gain.
Bromocriptine suppresses lactation by inhibiting prolactin secretion. It is contraindicated in breastfeeding women due to the intended suppression of milk production. No M/P ratio available; minimal excretion into breast milk is expected but not well studied.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and enhanced renal clearance may reduce serum concentrations of dextroamphetamine. Dose adjustment may be necessary based on clinical response; start with lowest effective dose and monitor for worsening ADHD symptoms. Avoid in severe hypertension or preeclampsia.
No specific dose adjustments are recommended for pregnancy; however, the drug is generally discontinued once pregnancy is confirmed unless necessary for prolactinoma treatment. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may theoretically alter levels, but data are insufficient to recommend dose changes.
Monitor for hypertension, tachycardia, and mental status changes (psychosis, mania) especially at high doses. Avoid late-day dosing to prevent insomnia. Use with caution in patients with pre-existing cardiovascular disease or hyperthyroidism. Dextroamphetamine can suppress appetite and cause weight loss; monitor growth in children. Abuse potential is high; schedule II controlled substance. Can precipitate tics in susceptible individuals. Contraindicated within 14 days of MAOIs due to hypertensive crisis.
Titrate slowly to minimize orthostatic hypotension and gastrointestinal upset. Administer with food to reduce nausea. Monitor for pulmonary fibrosis and Raynaud phenomenon with long-term use. Avoid concomitant use with ergot alkaloids due to additive vasospasm risk.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew the extended-release capsules; swallow whole.,Avoid taking the medication in the evening or close to bedtime to prevent trouble sleeping.,Report any chest pain, shortness of breath, fainting, or rapid heart rate to your doctor immediately.,Contact your doctor if you experience new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,You may experience decreased appetite and weight loss; maintain a healthy diet and inform your doctor if weight loss is significant.,Do not stop taking abruptly; taper dose under medical supervision to avoid withdrawal symptoms.,This medication has potential for abuse and dependence; keep in a safe place and do not share with others.,Avoid alcohol and caffeine as they may increase side effects like jitteriness and heart palpitations.,Tell all healthcare providers you are taking this medication, especially before surgery or dental procedures.
Take with food to reduce nausea and lightheadedness.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol as it may worsen side effects.,Report persistent cough, chest pain, or changes in urination or vision.,Do not stop abruptly; taper under medical supervision.
No interactions on record
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Concurrent use of bromocriptine, a dopamine D2 receptor agonist, and enasidenib, an IDH2 inhibitor, may lead to increased risk of central nervous system adverse effects, including dizziness, somnolence, and extrapyramidal symptoms. Enasidenib inhibits CYP3A4, which metabolizes bromocriptine, potentially elevating bromocriptine plasma concentrations. This pharmacokinetic interaction can exacerbate dopaminergic toxicity, especially in patients with hepatic impairment or those on high-dose bromocriptine."
"Bromocriptine, a dopamine D2 receptor agonist and ergot derivative, is primarily metabolized by CYP3A4. Astemizole, a second-generation antihistamine, is also metabolized by CYP3A4. Concomitant use of these two drugs can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of both agents. Elevated bromocriptine levels raise the risk of ergotism (vasospasm, ischemia) and neuropsychiatric toxicities, while increased astemizole concentrations may prolong the QT interval, predisposing patients to life-threatening ventricular arrhythmias such as torsades de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXEDRINE vs BROMOCRIPTINE MESYLATE, answered by our medical review team.
DEXEDRINE is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.. BROMOCRIPTINE MESYLATE is a Dopamine Agonist that works by Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXEDRINE and BROMOCRIPTINE MESYLATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXEDRINE is: 5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.. The standard adult dose of BROMOCRIPTINE MESYLATE is: Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXEDRINE and BROMOCRIPTINE MESYLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXEDRINE is classified as Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of pr. BROMOCRIPTINE MESYLATE is classified as Category A/B. First trimester: Limited human data; animal studies show increased fetal resorption and growth retardation at high doses. Second and third trimesters: Risk of postpartum hemorrhage. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.